Biomedical Engineering Reference
In-Depth Information
84. Twyman RM, Schillberg S, Fischer R. (2005) Transgenic
plants in the biopharmaceutical market. Expert Opin. Emerg.
Drugs 10, 185-218.
85. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR.
(2010) Novel approaches to vaginal delivery and safety of
microbicides: biopharmaceuticals, nanoparticles, and vac-
cines. Antiviral. Res. 88, S55-S66.
86. Singh N, Pandey A, Mittal SK. (2011) Avian influenza pandemic
preparedness: developing prepandemic and pandemic vaccines
against a moving target. Expert Rev. Mol. Med. 12, e14.
87. Yusibov V, Rabindran S. (2008) Recent progress in the
development of plant-derived vaccines. Expert Rev. Vaccines
7, 1173-1183.
88. Rybicki EP. (2010) Plant-made vaccines for humans and
animals. Plant Biotechnol. J. 8, 620-637.
89. Hiatt A, Cafferkey R, Bowdish K. (1989) Production of
antibodies in transgenic plants. Nature 342, 76-78.
90. Mason HS, Lam DMK, Arntzen CJ. (1992) Expression of
hepatitis B surface antigen in transgenic plants. Proc. Natl.
Acad. Sci. U. S. A. 89, 11745-11749.
91. Yusibov V, Streatfield SJ, Kushnir N. (2011) Clinical devel-
opment of plant-produced recombinant pharmaceuticals: vac-
cines, antibodies, and beyond. Human Vaccines 7, 1-9.
92. Pujol M, Ramirez NI, Ayala M, Gavilondo JV, Valdes R,
Rodriguez M, et al. (2005) An integral approach towards a
practical application for a plant-made monoclonal antibody in
vaccine purification. Vaccine 23, 1833-1837.
93. Santi L. (2009) Plant derived veterinary vaccines. Vet. Res.
Commun. 33, S61-S66.
94. Rybicki EP. (2009) Plant-produced vaccines: promise and
reality. Drug Discov. Today 14, 16-24.
95. Ahmad A, Pereira EO, Conley AJ, Richman AS, Menassa R.
(2010) Green biofactories: recombinant protein production in
plants. Recent Patents Biotechnol. 4, 242-259.
96. Gleba Y, Klimyuk V, Marillonnet S. (2005) Magnifection—a
new platform for expressing recombinant vaccines in plants.
Vaccine 23, 2042-2048.
97. Zhang X, Guda C, Datta R, Dute R, Urry DW, Daniell H.
(1995) Nuclear expression of an environmentally friendly
synthetic protein based polymer gene in tobacco cells. Bio-
technol. Lett. 17, 1279-1284.
98. Zhang XR, Urry DW, Daniell H. (1996) Expression of an
environmentally friendly synthetic protein-based polymer
gene in transgenic tobacco plants. Plant Cell Rep. 16, 174-179.
99. Guda C, Zhang X, Mcpherson DT, Xu J, Cherry JH, Urry DW,
et al. (1995) Hyper expression of an environmentally friendly
synthetic-polymer gene. Biotechnol. Lett. 17, 745-750.
100. Scheller J, Henggeler D, Viviani A, Conrad U. (2004) Purifica-
tion of spider silk-elastin from transgenic plants and application
for human chondrocyte proliferation. Transgenic Res. 13, 51-57.
101. Scheller J, Guhrs KH, Grosse F, Conrad U. (2001) Production
of spider silk proteins in tobacco and potato. Nat. Biotechnol.
19, 573-577.
102. Junghans F, Morawietz M, Conrad U, Scheibel T, Heilmann
A, Spohn U. (2006) Preparation and mechanical properties of
layers made of recombinant spider silk proteins and silk from
silk worm. Appl. Phys. A Mater. Sci. Process. 82, 253-260.
103. Junghans F, Conrad U, Heilmann A, Spohn U. (2008) Micro-
mechanical investigations on films made of recombinant
spider silk proteins and silk fibroin. Mater. Res. Soc.
Symp. Proc Mater. Res. Soc. 1062.
104. Patel J, Zhu H, Menassa R, Gyenis L, Richman A, Brandle J.
(2007) Elastin-like polypeptide fusions enhance the accumu-
lation of recombinant proteins in tobacco leaves. Transgenic
Res. 16, 239-249.
105. Scheller J, Leps M, Conrad U. (2006) Forcing single-chain
variable fragment production in tobacco seeds by fusion to
elastin-like polypeptides. Plant Biotechnol. J. 4, 243-249.
106. Fiedler U, Conrad U. (1995) High-level production and long-
term storage of engineered antibodies in transgenic tobacco
seeds. Biotechnology (N Y) 13, 1090-1093.
107. Stoger E, Ma JKC, Fischer R, Christou P. (2005) Sowing the
seeds of success: pharmaceutical proteins from plants. Curr.
Opin. Biotechnol. 16, 167-173.
108. Joensuu JJ, Brown KD, Conley AJ, Clavijo A, Menassa R,
Brandle JE. (2009) Expression and purification of an anti-
foot-and-mouth disease virus single chain variable antibody
fragment in tobacco plants. Transgenic Res. 18, 685-696.
109. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et
al. (2001) Soluble gp130 is the natural inhibitor of soluble
interleukin-6 receptor transsignaling responses. Eur. J. Bio-
chem. 268, 160-167.
110. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert
D. (2007) The IL-6/sIL-6R complex as a novel target for
therapeutic approaches. Expert Opin. Ther. Targets 11, 613-
624.
111. NowellMA, Richards PJ, Horiuchi S, YamamotoN, Rose-John
S, Topley N, et al. (2003) Soluble IL-6 receptor governs IL-6
activity in experimental arthritis: blockade of arthritis severity
by soluble glycoprotein 130. J. Immunol. 171, 3202-3209.
112. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle
PR, et al. (2005) IL-6 signaling promotes tumor growth in
colorectal cancer. Cell Cycle 4, 217-220.
113. Lin M, Rose-John S, Grotzinger J, Conrad U, Scheller J.
(2006) Functional expression of a biologically active frag-
ment of soluble gp130 as an ELP-fusion protein in transgenic
plants: purification via inverse transition cycling. Biochem. J.
398, 577-583.
114. Floss DM, Sack M, Stadlmann J, Rademacher T, Scheller J,
Stoger E, et al. (2008) Biochemical and functional character-
ization of anti-HIVantibody-ELP fusion proteins from trans-
genic plants. Plant Biotechnol. J. 6, 379-391.
115. Floss DM, Sack M, Arcalis E, Stadlmann J, Quendler H,
Rademacher T, et al. (2009) Influence of ELP fusions on the
quantity and quality of a tobacco-derived HIV-neutralizing
antibody. Plant Biotechnol. J. 7, 899-913.
116. Plagmann I, Chalaris A, Kruglov AA, Nedospasov SA, Rose-
nstiel P, Rose-John S, et al. (2009) Transglutaminase-cata-
lyzed covalent multimerization of camelidae anti-human
TNF single domain antibodies improves neutralizing activity.
J. Biotechnol. 142, 170-178.
Search WWH ::
Custom Search